Psychiatry & Neurology Doctors in Farmington, UT Accepting Medicare

4 Psychiatry & Neurology doctors found. Showing 1 - 4

David F Wilson, D.O. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1433 N 1075 W, Ste 120, Farmington, UT 84025 Phone: 385-294-7661

Dr. Shawn Jeffrey Kohler, M.D. PHD. Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 291 S 200 W, Farmington, UT 84025 Phone: 801-213-3770

Dr. Matthew J Gardiner, MD Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 808 Spring Pond Dr, Farmington, UT 84025 Phone: 801-510-2543

Dr. Kara Arnold Applegate, M.D. Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 240 N East Promontory Ste 200, Farmington, UT 84025 Phone: 801-382-8238    Fax: 801-758-2001

News Archive

Connecticut House approves two health insurance pooling bills

The Connecticut House on Wednesday approved two separate measures to expand health insurance pooling in the state, the Hartford Courant reports. The first measure would create a public health insurance pool open to all residents.

HHS appoints new members to Presidential Advisory Council on HIV/AIDS

Health and Human Services Secretary Kathleen Sebelius announced today the appointment of 24 new members to the Presidential Advisory Council on HIV/AIDS (PACHA). The PACHA's chair, Dr. Helene Gayle, was appointed in August 2009.

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, China.

Thoratec board authorizes repurchase of additional $50M of common stock

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that its Board of Directors has authorized the repurchase of an additional $50 million of the company's shares of common stock over the next year.

New technique improves accuracy of CRISPR/Cas9 gene editing system

A new CRISPR/Cas9 technology developed by scientists at the University of Massachusetts Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.

Read more Medical News

› Verified 6 days ago